Neural restrictive silencer factor and choline acetyltransferase expression in cerebral tissue of Alzheimer's Disease patients: A pilot study

• Published in: Genetics and molecular biology 2013-01, Vol.36 (1), p.28-36
• Main Authors: González-Castañeda, Rocío E, Sánchez-González, Víctor J, Flores-Soto, Mario, Vázquez-Camacho, Gonzalo, Macías-Islas, Miguel A, Ortiz, Genaro G
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; BIOCHEMISTRY & MOLECULAR BIOLOGY; brain; choline acetyltransferase; GENETICS & HEREDITY; Human and Medical Genetics; neural restrictive silencer factor; protein expression
• ISSN: 1415-4757; 1678-4685; 1415-4757; 1678-4685
• DOI: 10.1590/s1415-47572013000100005

Decreased Choline Acetyltransferase (ChAT) brain level is one of the main biochemical disorders in Alzheimer's Disease (AD). In rodents, recent data show that the CHAT gene can be regulated by a neural restrictive silencer factor (NRSF). The aim of the present work was to evaluate the gene and protein expression of CHAT and NRSF in frontal, temporal, entorhinal and parietal cortices of AD patient brains. Four brains from patients with AD and four brains from subjects without dementia were studied. Cerebral tissues were obtained and processed by the guanidine isothiocyanate method for RNA extraction. CHAT and NRSF gene and protein expression were determined by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. CHAT gene expression levels were 39% lower in AD patients as compared to the control group (p < 0.05, U test). ChAT protein levels were reduced by 17% (p = 0.02, U test). NRSF gene expression levels were 86% higher in the AD group (p = 0.001, U test) as compared to the control group. In the AD subjects, the NRSF protein levels were 57% higher (p > 0.05, U test) than in the control subjects. These findings suggest for the first time that in the brain of AD patients high NRSF protein levels are related to low CHAT gene expression levels.